Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4685029 | 0.78 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4686993 | 0.74 | DPP4 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4681145 | 0.74 | HTT (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2991774 | 0.72 | HTT (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4681766 | 0.72 | HTT (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4684804 | 0.70 | CHRM2 (0.34) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14339515 | 0.70 | CHRNB2 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1535527 | 0.66 | JAK2 (0.36) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL4670206 | 0.64 | PKM (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL23064505 | 0.63 | TDP1 (0.61) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110294701-B | Synthetic method of 5-methyl-2-pyrrolidone or derivatives thereof | 厦门大学 | 2021-07-09 | — | — | CN | disclosed |
| CN-110294701-A | A kind of synthetic method of 5- N-methyl-2-2-pyrrolidone N or derivatives thereof | 厦门大学 | 2019-10-01 | — | — | CN | disclosed |
| US-7129362-B2 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| CN-1764379-A | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone | DU PONT (US) | 2006-04-26 | — | — | CN | disclosed |
| US-20050137406-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | E. I. DU PONT DE NEMOURS AND COMPANY | 2005-06-23 | — | — | US | disclosed |
| US-20050038265-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | MANZER LEO ERNEST (US) | 2005-02-17 | — | — | US | disclosed |
| US-20050033062-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | MANZER LEO ERNEST (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050033063-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | MANZER LEO ERNEST (US) | 2005-02-10 | — | — | US | disclosed |
| US-20040192938-A1 | Production of 5-mehyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033063-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | ALDH18A1, PNPO, ABAT | CHRM2 1774/4885CHRM4 2162/4885CHRM5 580/4885 |
| US-20050137406-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | ALDH18A1, PNPO, ABAT | CHRM2 1906/4885CHRM4 2310/4885CHRM5 674/4885 |
| US-20040192938-A1 | Production of 5-mehyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive of levulinic acid esters with aryl and alkyl amines | PAH, ALDH18A1, PNPO | CHRM2 1879/4885CHRM4 1976/4885CHRM5 449/4885 |
| US-20050038265-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | ALDH18A1, PNPO, ABAT | CHRM2 1774/4885CHRM4 2162/4885CHRM5 580/4885 |
| US-20050033062-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-alkyl-2-pyrrolidone by reductive amination of levulinic acid esters with aryl and alkyl amines | ALDH18A1, PNPO, ABAT | CHRM2 1774/4885CHRM4 2162/4885CHRM5 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.